SecBot SecBot
Institutional Cluster

ABCL

AbCellera Biologics Inc.
BEARISH
Impact 6/10
Horizonimmediate Processed3mo ago
Institutional cluster: 5 buyers, 7 sellers (mixed)
Actionable Insight ▼ Bearish

The $200M offering filed 4 days ago is the dominant near-term catalyst, expect continued selling pressure from dilution. The institutional buying cluster (especially BofA doubling) suggests some long-term conviction, but Goldman's near-exit and UBS trim indicate smart money is reducing exposure. Monitor the offering pricing and any insider buying post-offering for a potential floor.

DirectionBearish
Confidencemedium
Horizonimmediate

ABCL635

● Neutral Named in this fund cluster
Impact
Phase
Phase 2
Time to market
Phase 3 is planned to begin in 2027. Assuming a multi-year Phase 3 program followed by FDA review, potential approval would likely be 2029-2030 at the earliest, barring accelerated development.
Next catalyst
None dated

What to watchThe next major catalyst for ABCL635 is the planned Phase 3 start in 2027, which the company confirmed on its Q3 2026 earnings call. Positive Phase 2 data (83% vs 33% placebo reduction in hot flash frequency) has already been reported, so the stock's next binary event is likely years away. Watch for FDA feedback on Phase 3 trial design and any partnership/licensing deals that could validate the asset's value.

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$11.20
T+0 close · Aug 15, 2026 · via day close
Latest settled
+11.25%
T+60 · $12.46
Vs SPY
+14.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 17 $11.20entry
  2. T+1 · 3mo ago −0.71%α −0.04% · $11.12
  3. T+5 · 3mo ago −5.27%α −4.08% · $10.61
  4. T+20 · 2mo ago +1.88%α +3.85% · $11.41
  5. T+60 · 7d ago +11.25%α +14.19% · $12.46

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AbCellera Biologics (ABCL) saw a mixed institutional cluster in Q2 2026: 5 buyers added $51.3M in new positions (dominated by BofA and National Bank of Canada), while 7 sellers reduced holdings by $11.1M (led by Goldman Sachs near-exit). The buying is concentrated in mega-passive and asset managers, suggesting index rebalancing and opportunistic accumulation post-Phase 2 data, but the selling by Goldman Sachs and UBS signals caution. The cluster is corroborated by insider buying ($865K from C-suite), but the 424B5 filing 4 days ago for a $200M dilutive offering overrides the bullish signal, creating a bearish near-term dynamic despite positive clinical news.

Key Financial Metrics

Direction
mixed
Buy Value
$62.5M
Sell Value
$11.1M
Net Flow
$40.2M

Institutional Positions

Net institutional flow: $40.2M

▲ Buyers (5)

InstitutionActionChangePosition ValueValue Δ
BofADOUBLED+104.7%$48.2M$37.7M
National Bank Of CanadaDOUBLED+88415%$9.7M$9.7M
Bank Of Montreal /CanDOUBLED+165.7%$3.8M$3.2M

▼ Sellers (7)

InstitutionActionChangePrev ValueValue Δ
Goldman SachsNEAR_EXIT-93.7%$13.1M-$11.2M
UBSTRIM-55.6%$14.7M-$5.1K
JPMorganTRIM-71.8%$255.0K-$77.2K

Key Facts

  • 5 institutional buyers added $51.3M in Q2 2026, led by BofA (+$37.7M) and National Bank of Canada (+$9.7M)
  • 7 institutional sellers reduced holdings by $11.1M, led by Goldman Sachs near-exit (-$11.2M) and UBS trim (-$5K)
  • Insider buying of $865K from C-suite corroborates institutional accumulation
  • A $200M dilutive public offering was filed 4 days ago (424B5), creating significant dilution overhang
  • Goldman Sachs reduced its position by 93.7%, signaling potential concern about valuation or dilution

Financial Impact

Net institutional buying of $40.2M ($51.3M bought vs $11.1M sold) in Q2 2026, but followed by a $200M dilutive offering

dilutioninstitutional ownershipcash position

Risk Factors

  • $200M dilutive offering will significantly increase share count and depress near-term price
  • Goldman Sachs and UBS reducing positions suggests institutional skepticism
  • Positive Phase 2 data may be fully priced in, with no near-term catalyst to offset dilution

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-ABCL-2026-Q2

Track record

16 reports on ABCL

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +127.09% at T+20 after the Jul 29, 2026 report. 6 of 9 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $11.63 settles Feb 12
  2. Nov 13, 20263d ago Insider Cluster Bullish 4/10 Entry $11.49 settles Feb 11
  3. Nov 13, 20263d ago Insider Cluster Bullish 4/10 Entry $11.49 settles Feb 11
  4. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $12.46 settles Feb 8
  5. Aug 24, 202612w ago Insider Cluster Mixed 5/10 Entry $12.50 settles Nov 18
  6. Aug 18, 202612w ago Insider Cluster Bullish 5/10 Entry $11.12 to $11.95 ▲ +7.46% +8.46% vs SPY
  7. Aug 15, 202613w ago Institutional Cluster Bearish 6/10 Viewing Entry $11.20 to $12.46 ▼ −11.25% −14.19% vs SPY
  8. Aug 11, 202613w ago 424B5 Bearish 7/10 Entry $10.36 to $11.13 ▼ −7.48% −12.60% vs SPY
  9. Aug 10, 202614w ago 8-K Bullish 7/10 Entry $9.34 to $12.18 ▲ +30.41% +32.82% vs SPY
  10. Jul 29, 202615w ago 8-K Bullish 6/10 Entry $5.39 to $11.37 ▲ +110.95% +106.22% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (9h 45m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 15, 2026